Quick answer
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $958.4M and net loss of $288.3M for the fiscal year ended 2025-12-31, up 432.1% from $180.1M the year before, per its 10-K filed with the SEC on 2026-02-19. Long-term debt stood at $339.9M.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $958.4M | -$288.3M | $339.9M |
| 2024 (FY ending 2024-12-31) | $180.1M | -$465.9M | $117.6M |
| 2023 (FY ending 2023-12-31) | $0.0M | -$373.6M | $115.5M |
| 2022 (FY ending 2022-12-31) | $0.0M | -$295.4M | $69.7M |
| 2021 (FY ending 2021-12-31) | $0.0M | -$241.8M | $0.0M |
| 2020 (FY ending 2020-12-31) | $0.0M | -$202.2M | — |
| 2019 (FY ending 2019-12-31) | $0.0M | -$83.9M | — |
| 2018 (FY ending 2018-12-31) | $0.0M | -$32.8M | — |
| 2017 (FY ending 2017-12-31) | $0.0M | -$31.2M | — |
| 2016 (FY ending 2016-12-31) | — | -$26.4M | — |
Frequently asked questions
What is Madrigal Pharmaceuticals, Inc.'s annual revenue?
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $958.4M and net loss of $288.3M for the fiscal year ended 2025-12-31, up 432.1% from $180.1M the year before, per its 10-K filed with the SEC on 2026-02-19. Long-term debt stood at $339.9M.
What is MDGL's profit margin?
Madrigal Pharmaceuticals, Inc.'s net margin was -30.1% in the fiscal year ended 2025-12-31.
Related
- MCK revenue, net income and debt history (McKESSON CORPORATION)
- MCO revenue, net income and debt history (Moody'S Corporation)
- MDB revenue, net income and debt history (Mongodb, Inc.)
- MDLN revenue, net income and debt history (Medline Inc.)
- MDLZ revenue, net income and debt history (Mondelez International, Inc.)
- MDT revenue, net income and debt history (Medtronic plc)
- MEDP revenue, net income and debt history (Medpace Holdings, Inc.)
- MELI revenue, net income and debt history (MercadoLibre, Inc.)
Last updated Oct 16, 2026, 10:42 PM ET. Data only, not financial or tax advice.